Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells

Apoptosis

Volumn 12, Issue 4, 2007, Pages 657-669

  Pratt, M A Christine ^a   White, Dawn ^a   Kushwaha, Neena ^a   Tibbo, Emma ^a   Niu, Min Ying ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bcl 2; Breast cancer; Estrogen transcriptional regulation; p53 mutation

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; ESTROGEN RECEPTOR; HERPESVIRUS VECTOR; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOPLASM; DNA BINDING MOTIF; GENE ACTIVITY; GENE CONSTRUCT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEAR LOCALIZATION SIGNAL; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REPORTER GENE; TRANSCRIPTION REGULATION; WILD TYPE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MUTATION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; REGULATORY SEQUENCES, NUCLEIC ACID; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE;

EID: 33947170327     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-0023-y     Document Type: Article

References (38)

1. Allsopp TE, Wyatt S, Paterson HF, Davies AM (1993) The proto-oncogene Bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 73:295-307
2. Bissonnette RP, Echeverri F, Mahboubi A, Green DR (1992) Apoptotic cell death induced by c-myc is inhibited by Bcl-2. Nature 359:552-554
3. Garcia I, Martinou I, Tsujimoto Y, Martinou J-C (1992) Prevention of programmed cell death of sympathetic neurons by the Bcl-2 proto-oncogene. Science 258:302-304
4. Miyashita T, Reed JC (1992) Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411
5. Gross AJ, McDonnell M, Korsmeyer SJ (1999) Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911
6. Deveraux QL, Schendel SL, Reed JC (2001) Anti-apoptotic proteins. The Bcl-2 and inhibitor of apoptosis protein families. Cardiol Clin 19:57-74
7. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054-1072
8. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
9. White E (1996) Life, death, and the pursuit of apoptosis. Genes Dev 10:1-15
10. Kokontis JM, Wagner AJ, O'Leary M, Liao S, Hay N (2001) A transcriptional activation function of p53 is dispensible for and inhibitory of its apoptotic function. Oncogene 20:659-668
11. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M (1995) Induction of apoptosis in HeLa cells by transactivation deficient p53. Genes Dev 9:2170-2183
12. Moll UM, Riou G, Levine AJ (1995) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 92:4407-4411
13. Fontoura BM, Atienza CA, Sorokina EA, Morimoto T, Carroll RB (1997) Cytoplasmic p53 polypeptide is associated with ribosomes. Mol Cell Biol 17:3146-3154
14. Clarke R, Skaar T, Baumann K et al (1994) Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat 31:237-248
15. Santen RJ, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11:221-65
16. Teixeira C, Reed JC, Pratt MA (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907
17. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69:135-139
18. Bhargava V, Kell DL, van de Rijn M, Warnke RA (1994) Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540
19. Young RL, Korsmeyer SJ (1993) A negative regulatory element in the Bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 13:3686-3697
20. Dong L, Wang W, Wang F et al (1999) Mechanisms of transcriptional activation of Bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274:32099-32107
21. Perillo B, Sasso A, Abbondanza C, Palumbo G (2000) 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing Bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20:2890-2901
22. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM (1994) Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095-2097
23. Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res 54:3131-3135
24. Harigai M, Miyashita T, Hanada M, Reed JC (1996) A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. Oncogene 12:1369-1374
25. Crook T, Vousden KH (1992) Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 1:3935-3940
26. Marston N J, Crook T, Vousden KH (1994) Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9:2707-2716
27. Concin N, Zeillinger C, Tong D et al (2003) Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 breast carcinoma cell lines. Breast Can Res Treat 79:37-46
28. Pratt MA, Krajewski S, Menard M, Krajewska M, Macleod H, Reed JC (1998) Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2. FEBS Lett 440:403-408
29. Shen Y, Shenk T (1994) Relief of p53-mediated transcriptional repression by the adenovirus E1B 19 kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci USA 91:8940-8944
30. Mihara M, Erster S, Zaika A et al (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11:577-590
31. O'Connor PM, Jackman J, Bae I et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300
32. Wu Y-I, Mehew JW, Heckman CA, Arcinas M, Boxer LM (2001) Negative regulation of Bcl-2 expression by p53 in hematopoietic cells. Oncogene 20:240-251
33. Miyashita T, Krajewski S, Krajewska M et al (1994) Tumor suppressor p53 is a regulator of Bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805
34. Ameyar M, Shatrov V, Bouquet C et al (1999) Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF-7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 18:5464-5472
35. Trisciuoglio D, Iervolino A, Candiloro A et al (2004) Bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity. J Biol Chem 279:6737-6745
36. Wang Z, Zhang B, Wang M, Carr BI (2003) Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to ppRSK. J Biol Chem 278:11138-11145
37. Ioakim-Liossi A, Karakitsos P, Markopoulos C et al (2001) p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas. Cytopathology 2:197-202
38. Dong L, Wang W, Wang F et al (1999) Mechanisms of transcriptional activation of Bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274:32099-32107